Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | CCKBR | P32239 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4196071 | 0.87 | MAPT (0.53) | MAPTTP53POLBCCKBRL3MBTL1 | |
| SCHEMBL4207725 | 0.86 | TP53 (0.41) | MAPTTP53POLBNPC1RAB9A | |
| SCHEMBL4207573 | 0.85 | PTGES2 (0.51) | MAPTTP53POLBL3MBTL1NPC1 | |
| SCHEMBL4204582 | 0.84 | TP53 (0.45) | MAPTTP53POLBNPC1RAB9A | |
| SCHEMBL4196383 | 0.82 | RAB9A (0.46) | TP53NPC1RAB9AHTR6QRFPR | |
| SCHEMBL4206144 | 0.82 | GHSR (0.51) | TP53NPC1RAB9A | |
| SCHEMBL4204580 | 0.80 | MAPK1 (0.53) | MAPTPOLBHTR6QRFPR | |
| SCHEMBL4209408 | 0.80 | SMN1; SMN2 (0.47) | MAPTPOLBL3MBTL1HTR6QRFPR | |
| SCHEMBL4207708 | 0.79 | GABRA1 (0.47) | TP53CCKBRNPC1RAB9AHTR6 | |
| SCHEMBL4201683 | 0.78 | HTR6 (0.45) | TP53POLBRAB9AHTR6QRFPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | claimed |
| EP-1888517-A1 | NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | claimed |
| WO-2006126939-A1 | NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | claimed |
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-1888517-A1 | NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006126939-A1 | NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | HTR6, HTR1A, HTR1D | MAPT 2052/4885TP53 4243/4885POLB 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.